Cargando…

Targeting BCL10 by small peptides for the treatment of B cell lymphoma

Rationale: Constitutive activation of the NF-κB signalling pathway plays a pivotal role in the pathogenesis of activated B cell-like diffuse large B-cell lymphomas (ABC-DLBCLs), the most aggressive and chemoresistant form of DLBCL. In ABC-DLBCLs, the CARMA1-BCL10 (CB) complex forms a filamentous str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Wei, Sun, Chenxia, Sun, Xiaochen, He, Miaoxia, Yu, Haolan, Yan, Wenfen, Wen, Fuping, Zhang, Liang, Yang, Chenghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546004/ https://www.ncbi.nlm.nih.gov/pubmed/33052237 http://dx.doi.org/10.7150/thno.47533

Ejemplares similares

Targeting the Bcl-2 Family in B Cell Lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Infrequent BCL10 Mutations in B‐Cell Non‐Hodgkin's Lymphomas
por: Takahashi, Hidenobu, et al.
Publicado: (1999)

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma
por: Fan, Qian, et al.
Publicado: (2016)

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
por: Jia, Gaozhen, et al.
Publicado: (2017)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
por: Dupont, Thibault, et al.
Publicado: (2015)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
por: Mahmoud, Hanan Mohamed, et al.
Publicado: (2011)

Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma
por: Su, Yinghan, et al.
Publicado: (2016)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

The distinct clinical features and prognosis of the CD10(+)MUM1(+) and CD10(−)Bcl6(−)MUM1(−) diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2016)

Bcl10 is not a target for frequent mutation in human carcinomas
por: Lambers, A R, et al.
Publicado: (1999)

A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
por: Lavik, Andrew R., et al.
Publicado: (2015)

MicroRNA-148b enhances the radiosensitivity of B-cell lymphoma cells by targeting Bcl-w to promote apoptosis
por: Liu, Si-hong, et al.
Publicado: (2020)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival Bcl-2 family proteins
por: Wang, Haolan, et al.
Publicado: (2023)

Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice
por: Masle-Farquhar, Etienne, et al.
Publicado: (2021)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

Bcl10 mutations in malignancy
por: Dyer, M J S
Publicado: (1999)

Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas
por: Goteri, Gaia, et al.
Publicado: (2011)

Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2022)

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
por: Wei, Hudie, et al.
Publicado: (2023)

Targeting mitochondrial respiration and the BCL2 family in high‐grade MYC‐associated B‐cell lymphoma
por: Donati, Giulio, et al.
Publicado: (2021)

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
por: Rossi, Alessandra, et al.
Publicado: (2021)

Small-molecule Bcl-2 antagonists as targeted therapy in oncology
por: Warr, M.R., et al.
Publicado: (2008)

Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case
por: Ittel, A, et al.
Publicado: (2015)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
por: Abbott, David R., et al.
Publicado: (2009)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
por: Wobser, M, et al.
Publicado: (2007)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma
por: Ali, Seemal, et al.
Publicado: (2022)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
por: Moore, Alison M., et al.
Publicado: (2018)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-X(L )and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model
por: Arnold, Alan A, et al.
Publicado: (2008)

The epigenetic regulator CTCF modulates BCL6 in lymphoma
por: Batlle-López, Ana, et al.
Publicado: (2015)

Corrigendum: Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kugn4d2l0jgmas1r0opv8qrumf